ANIP
ANI Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
21.97
PEG
0.04
P/B
2.86
P/S
1.96
EV/EBITDA
7.86
DCF Value
$1,140.11
FCF Yield
7.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.1%
Operating Margin
12.6%
Net Margin
8.6%
ROE
15.5%
ROA
5.3%
ROIC
7.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $247.1M | $27.5M | $1.17 |
| FY 2025 | $883.4M | $78.3M | $3.32 |
| Q3 2025 | $227.8M | $24.1M | $1.13 |
| Q2 2025 | $211.4M | $8.5M | $0.36 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.43
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.